Table 2.
Literature search CT-IGRT outcomes
| Source | Type of study | Treatment | PTV (mm) | Pts | Follow-up (y) | Biochemical relapse | Cancer death | GI A 2 | GI A 3+ | GU A 2 | GU A 3+ | GI C 2 | GI C 3+ | GU C 2 | GU C 3+ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Raziee25 | Retro | CBCT: IMRT or VMAT | 7–10 | 355 | 4.9 ci | 9% at 5y | 0% at 8y | 7.3 | 0 | NR | NR | 3.1 | NR | 1.4 | |
| Ingrosso26 | Retro | CBCT: CRT (linac or micro MLC) | 5–6 | 294 | 5.24 ci | 13% at 5y | 4% at 5y | 11.5 | 0.6 | 31.9 | 2 | 2.7 | 2.3 | 7.5 | 3.4 |
| Shimizu27 | Pro | MVCT: IMRT (HT) | 5 | 138 | 5 ci | 9.2% at 5y | 1.5% at 5y | NR | NR | NR | NR | 6.3 | 3.1 | 7.9 | 0 |
| Di Muzio28 | Pro | MVCT: IMRT (HT) | 8–10 | 211 | 5-act | 6.3% at 5y | 2.5% at 5y | 12.9 | 0.5 | 29 | 1.9 | 10.7 | 6.3 | 14.3 | 5.9 |
| Ingrosso29 | Pro | CBCT: IMRT | 6–8 | 118 | 4.51 ci | 13% at 4y | NR | 2.5 | 0 | 6.7 | 2.5 | 3.4 | 0 | 0.8 | 3.4 |
| Ishii30 | Pro | CBCT: VMAT | 5–8 | 224 | N/A | NR | NR | 10.7 | 0 | 11.6 | 0 | NR | NR | NR | NR |
| Nishimura31 | NR | MVCT: IMRT | 5 | 117 | 2.67 ci | NR | NR | NR | NR | NR | NR | 4.3 | 3.4 | 6.8 | 0 |
| Guckenberger32 | Pro | CBCT: IMRT | 5–10 | 150 | 4.17 ci | 18% at 5y | NR | 8.7 | 0 | 36.7 | 4 | 2.1 | 1.4 | 25.9 | 8 |
| Marina33 | Retro | CT (helical): IMRT or CRT | NR | 734 | N/A | 8% at 5y | 1% at 5y | NR | NR | NR | NR | NR | NR | NR | NR |
| Guckenberger34 | Pro | CBCT: IMRT | 10 | 100 | 2-i | NR | NR | 8 | 0 | 34 | 1 | 1.5 | 1.5 | 7.7 | 0 |
| Detti35 | Retro | CBCT: IMRT | 6–8 | 394 | 6.7y-ci | NR | NR | 25.6 | 0 | 51.8 | 0.5 | 3.3 | 0 | 3.1 | 0.2 |
| Jereczek-Fossa36 | Retro | CBCT: IMRT | 3–7 | 228 | 4 ci | 6% at 3y | NR | 8.3 | 0.4 | 21.5 | 3.9 | 2.1 | 0.8 | 4.8 | 0 |
| Tomita37 | Retro | MVCT: IMRT (HT) | 4–6 | 208 | 8.5 ci | 18% at 10y | 5% at 10y | NR | NR | NR | NR | 9.6 | 1.9 | 11.5 | 1.4 |
| Yamazaki38 | Retro | MVCT: IMRT (HT) | 3–5 | 270 | 6.17 ci | 10.8% at 5y | 0.2% at 5y | NR | NR | NR | NR | 4.1 | 1.9 | 4.1 | 0.4 |
| Marvaso39 | NR | CBCT: IMRT | 3–5 | 194 | 2.5 ci | 13% at 3y | NR | 2.6 | 0 | 9.8 | 1 | 0.5 | 0.5 | 3.1 | 0.5 |
| Sasaki40 | Retro | MVCT: IMRT (HT) | 3–5 | 274 | 5.17 ci | CNBC | NR | NR | NR | NR | NR | 4 | 1.8 | 4 | 0.4 |
| Arunsingh41 | Retro | CBCT/MVCT: IMRT (HT) | 5–7 | 101 | 2 ci | NR | NR | 20.8 | 0 | 6.9 | 0 | 14.9 | 5.9 | 10.9 | 3 |
| Krupa42 | NR | CBCT: VMAT | 8–10 | 158 | N/A | NR | NR | 1.3 | 0 | 13.9 | 1.9 | NR | NR | NR | NR |
| Girelli43 | Pro | CBCT: IMRT | 5–8 | 104 | 2.17 ci | 3.5% at 3y | 1.5% at 3y | 2.9 | 1 | 2.9 | 1.9 | 7.7 | 1.9 | 4.8 | 0 |
| Cheng44 | Retro | MVCT: IMRT (HT) | 3–6 | 146 | N/A | NR | NR | 32.9 | 0 | 36.9 | 0 | NR | NR | NR | NR |
| Average (%) | 0.0229a | 0.0036a | 11.33 | 0.19 | 22.58 | 1.58 | 5.15 | 2.24 | 7.81 | 1.75 |
A, acute; Act, actuarial; C, chronic; CBCT, cone-beam computed tomography; CNBC, could not be calculated; CRT, conformal radiation therapy;CT-IGRT, CT-guided radiotherapy; GI, gastrointestinal; GU, genitourinary ; HT, helical tomography; I, incidence; IMRT, intensity-modulated radiotherapy; MLC, multileaf collimator; MVCT, megavoltage computed tomography; N/A, not applicable; NR, not reported; PTV, planning treatment volume; Pro, prospective; Pts, patients; Retro, retrospective; SIB, simulVMAT, volumetric-modulated arc therapy; ci, cumulative incidence; y, year.
a
Incidence per year was calculated by averaging all the values in the column after applying the formula: (1-((1-(%/100))^(1/years).45